BRISTOL MYERS SQUIBB

🇫🇷France

Country: 🇫🇷France

Ownership: -

Established: 1989-01-01

Employees: 30K

Market Cap: $97.5B

Website: https://www.bms.com/

Clinical Trials

A Study to Evaluate the Pharmacokinetics of BMS-986141 in Participants With Hepatic Impairment Compared to Healthy Participants

Phase 1

Withdrawn

Conditions: Hepatic Impairment

Interventions: Drug: BMS-986141

First Posted Date: 2016-12-07

Last Posted Date: 2017-02-06

Lead Sponsor: Bristol-Myers Squibb

Registration Number: NCT02985632

Locations: 🇺🇸
Clinical Pharmacology of Miami, Miami, Florida, United States
🇺🇸
Texas Liver Institute, San Antonio, Texas, United States
🇺🇸
Clinical Research Center, Orlando, Florida, United States

A Study to Evaluate the Safety of Nivolumab and Ipilimumab in Subjects With Previously Untreated Advanced or Metastatic Renal Cell Cancer

Phase 4

Completed

Conditions: Renal Cell Carcinoma

Interventions: Drug: Nivolumab
Drug: Ipilimumab

First Posted Date: 2016-12-06

Last Posted Date: 2022-11-01

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 211

Registration Number: NCT02982954

Locations: 🇺🇸
Los Angeles Cancer Network, Los Angeles, California, United States
🇺🇸
Tennessee Oncology, PLLC - SCRI - PPDS, Chattanooga, Tennessee, United States
🇺🇸
Hollings Cancer Center, Charleston, South Carolina, United States

and more 56 locations

Single-dose Pharmacokinetics of BMS-986177 in Participants With Hepatic Impairment Compared to Healthy Participants

Phase 1

Completed

Conditions: Thrombosis

Interventions: Drug: BMS-986177

First Posted Date: 2016-12-05

Last Posted Date: 2018-11-14

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 26

Registration Number: NCT02982707

Locations: 🇺🇸
Orlando Clinical Research Center, Orlando, Florida, United States
🇺🇸
Clinical Pharmacology of Miami, Miami, Florida, United States
🇺🇸
Texas Liver Institute, San Antonio, Texas, United States

A Study of the Safety and Pharmacokinetics of Apixaban Versus Vitamin K Antagonist (VKA) or Low Molecular Weight Heparin (LMWH) in Pediatric Subjects With Congenital or Acquired Heart Disease Requiring Anticoagulation

Phase 2

Completed

Conditions: Thrombosis

Interventions: Drug: Vitamin K Antagonist (VKA)
Drug: Apixaban
Drug: Low Molecular Weight Heparin (LMWH)

First Posted Date: 2016-12-05

Last Posted Date: 2022-10-03

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 192

Registration Number: NCT02981472

Locations: 🇮🇹
Local Institution - 0026, Rome, Roma, Italy
🇺🇸
Children'S Hospital Colorado, Aurora, Colorado, United States
🇺🇸
Local Institution - 0013, Ann Arbor, Michigan, United States

and more 39 locations

Elotuzumab Safety Surveillance In Japanese Patients With Relapse Or Refractory Multiple Myeloma

Completed

Conditions: Multiple Myeloma

Interventions: Other: No Intervention

First Posted Date: 2016-11-29

Last Posted Date: 2019-08-20

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 500

Registration Number: NCT02976493

Locations: 🇯🇵
Local Institution, Shinjuku-ku, Tokyo, Japan

Trial to Evaluate the Efficacy and Safety of Abatacept in Combination With Standard Therapy Compared to Standard Therapy Alone in Improving Disease Activity in Adults With Active Idiopathic Inflammatory Myopathy

Phase 3

Completed

Conditions: Autoimmune Necrotizing Myopathy
Juvenile Myositis Above the Age of 18
Overlap Myositis
Polymyositis
Dermatomyositis

Interventions: Drug: Abatacept subcutaneous
Drug: Placebo

First Posted Date: 2016-11-23

Last Posted Date: 2023-10-30

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 149

Registration Number: NCT02971683

Locations: 🇲🇽
Local Institution - 0047, San Luis Potosi, Mexico
🇸🇪
Local Institution - 0037, Stockholm, Sweden
🇺🇸
Local Institution - 0018, Fort Lauderdale, Florida, United States

and more 76 locations

Safety Study of BMS-986016 With or Without Nivolumab in Patients With Advanced Solid Tumors

Phase 1

Active, not recruiting

Conditions: Cancer

Interventions: Drug: Relatlimab
Drug: Nivolumab

First Posted Date: 2016-11-17

Last Posted Date: 2024-08-20

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 35

Registration Number: NCT02966548

Locations: 🇯🇵
Local Institution - 0001, Kashiwa-shi, Chiba, Japan

A Study of Nivolumab Safety and Pharmacokinetics in Patients With Severe Sepsis or Septic Shock.

Phase 1

Completed

Conditions: Severe Sepsis

Interventions: Biological: Nivolumab

First Posted Date: 2016-11-10

Last Posted Date: 2019-04-23

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 38

Registration Number: NCT02960854

Locations: 🇺🇸
Univ. Of Colorado Health, Colorado Springs, Colorado, United States
🇺🇸
Pulmonary And Critical Care Of Atlanta, Atlanta, Georgia, United States
🇺🇸
Osf Saint Francis Medical Center, Peoria, Illinois, United States

and more 13 locations

A Study to Evaluate the Effect of Rifampin on the Single-dose Pharmacokinetics of BMS-986177 in Healthy Subjects

Phase 1

Completed

Conditions: Thrombosis

Interventions: Drug: BMS-986177
Drug: Rifampin

First Posted Date: 2016-11-08

Last Posted Date: 2017-01-06

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 16

Registration Number: NCT02959060

A Study to Evaluate the Effect of Rifampin on the Single-dose Pharmacokinetics (PK) of BMS-986141 in Healthy Subjects

Phase 1

Completed

Conditions: Atherothrombotic Diseases

Interventions: Drug: BMS 986141
Drug: Rifampin

First Posted Date: 2016-11-06

Last Posted Date: 2017-02-23

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 16

Registration Number: NCT02957448

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy